NPRA Safety Alerts
(Year 2024)
MADRAC Bulletin
Volume 51 Issue 06/2024
Click on the picture for more information.
MADRAC Bulletin
Volume 50 Issue 05/2024
Click on the picture for more information.
17-HYDROXYPROGESTERONE CAPROATE (17-OHPC)
17- Hydroxyprogesterone Caproate (17-OHPC): Cancellation of Product Registration and Product Recall
Click on the picture for more information.
PARACETAMOL
Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients
Click on the picture for more information.
FLUCONAZOLE
Updates on the Known Risk of Spontaneous Abortion During Pregnancy and Congenital Malformations in Children Exposed to Fluconazole in Utero
Click on the picture for more information.
PSEUDOEPHEDRINE
Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS)
Click on the picture for more information.
MEFENAMIC ACID
Mefenamic Acid- Associated Generalised Bullous Fixed Drug Eruption (GBFDE)
Click on the picture for more information.
PROGESTOGENS (CYPROTERONE ACETATE, MEDROXYPROGESTERONE ACETATE, CHLORMADINONE ACETATE)
Risk of Meningioma
Click on the picture for more information.
Paracetamol
Fixed Drug Eruptions (FDEs) associated with paracetamol
Click on the picture for more information.
MADRAC Bulletin
Volume 49 Issue 04/2024
Click on the picture for more information.
Azacitidine (Injectable Formulation)
Risk of Cutaneous Vasculitis
Click on the picture for more information.
17-Hydroxyprogesterone Caproate (17-OHPC)
Potential Cancer Risk in Offspring Exposed in Utero and Limited Efficacy Data
Click on the picture for more information.
Hydroxychloroquine
Risk of Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis)
Click on the picture for more information.
Anti-Clusters of Differentiation 20 (CD20) Antibodies (Rituximab, Obinutuzumab, Ofatumumab, Ocrelizumab)
Risk of Pyoderma Gangrenosum
Click on the picture for more information.
MADRAC Bulletin
Volume 48 Issue 03/2024
Click on the picture for more information.
Amoxicillin
Risk of Aseptic Meningitis
Click on the picture for more information.
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin)
Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration
Click on the picture for more information.
Olmesartan
Risk of Autoimmune Hepatitis
Click on the picture for more information.
Proton Pump Inhibitors
Risk of Erectile Dysfunction
Click on the picture for more information.
Levetiracetam and Clobazam
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Click on the picture for more information.
Hydrochlorothiazide
Risk of Acute Respiratory Distress Syndrome (ARDS)
Click on the picture for more information.
Ciprofloxacin, Moxifloxacin, Levofloxacin and Ofloxacin (Fluoroquinolones) for Systemic Use (Oral and Injection)
Risk of Suicidal Behaviours
Click on the picture for more information.
MADRAC Bulletin
Volume 47 Issue 02/2024
Click on the picture for more information.
Domperidone
Risk of Psychiatric Withdrawal Events When Used Off-Label for Lactation Stimulation
Click on the picture for more information.
Metformin
Risk of Vitamin B12 Deficiency
Click on the picture for more information.
Statins (Atorvastatin, Rosuvastatin, Simvastatin)
Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis
Click on the picture for more information.
MADRAC Bulletin
Volume 46 Issue 01/2024
Click on the picture for more information.
Imatinib
Risk of Thrombotic Microangiopathy
Click on the picture for more information.
Rivastigmine
Risks of QT Prolongation and Torsade de Pointes
Click on the picture for more information.
05-Jan-2024 (No. SP PPUM: 010/2024)
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia #8
Click on the picture below for more information.
English Version
Versi Bahasa Malaysia